Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but filing text confirms "Synthetic Blood International, Inc.")
Reporting Period: Quarterly period ended January 31, 1998 (Three and Nine Months).
Status: Development Stage Enterprise. The company is in the pre-clinical trial stage of its products and has not commenced principal operations. It faces substantial doubt regarding its ability to continue as a going concern without additional financing.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 1998 | Nine Months Ended Jan 31, 1998 | Accumulated Since Inception |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(149,842) | $(742,277) | $(9,029,409) |
| Net Loss Per Share (Basic/Diluted) | $(0.01) | $(0.02) | $(0.01) |
| Cash and Equivalents (Ending) | $2,862 | ||
| Working Capital Deficit | $(671,587) | ||
| Total Assets | $249,779 | ||
| Total Liabilities | $698,298 | ||
| Stockholders' Equity (Deficit) | $(448,519) |
Expenses (Nine Months 1998): Research and Development: $109,011; General and Administrative: $630,711; Interest: $3,731.
Material Changes vs. Prior Period
- Expense Reduction: Significant decrease in expenses compared to the prior year. R&D expenses dropped from $440,675 to $109,011 (nine months), and G&A dropped from $890,736 to $630,711. This was driven by reduced research personnel, fewer animal purchases, and lower legal/licensing fees.
- Net Loss Improvement: Net loss for the nine months ended Jan 31, 1998, was $742,277, a substantial reduction from $1,337,804 in the prior year period.
- Capital Structure: The company issued significant equity and debt to fund operations. During the nine months, the company raised $5,224,491 from the sale of common stock and $780,000 from convertible debentures.
- Cash Position: Cash decreased from $53,857 (April 30, 1997) to $2,862 (January 31, 1998), despite financing activities, due to high operating cash burn.
Outlook, Risks, and Management Commentary
- Going Concern Risk: Management explicitly states that the company's continuation is dependent on generating sufficient cash flow and obtaining additional financing. There is no assurance that FDA approval will be granted or that funding will be secured.
- Subsequent Event (Funding): On March 13, 1998, the company received $1,000,000 in funding. Conditions included officers forfeiting accumulated compensation ($186,851 reduction in accrued payroll) and transferring approximately 4.6 million shares of stock to a fundraising individual.
- Litigation: Two pending legal actions by former employees regarding a 1995 layoff. Management has accrued $124,000 for potential exposure.
- Future Needs: Significant additional financing is required to complete Phase I, II, and III human testing and FDA submission.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1,000,000 received in March 1998 against the current burn rate, given the ending cash balance of only $2,862.
- Debt Obligations: Review the terms of the $698,298 in total liabilities, specifically the $14,787 in stockholder loans and $233,852 in accrued payroll.
- Equity Dilution: Assess the impact of the 4.6 million shares transferred to the fundraising individual and the 4 million shares sold in the March 1998 funding round on existing shareholders.
- Regulatory Path: Confirm the current status of pre-clinical trials and the timeline for FDA submission, as the company has no revenue and relies entirely on future approval.
- Legal Exposure: Monitor the status of the $124,000 accrued litigation liability to ensure no additional costs arise.